Marc Beer

Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals, devices, and diagnostics. Marc founded Renovia in August 2016 and successfully closed a Series A and B financing with leading healthcare venture capital funds.

Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia.